ELGX Endologix Inc

Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the 30th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, CA.

Event: 30th Annual J.P. Morgan Healthcare Conference

Date: Wednesday, January 11, 2012

Time: 9:30 a.m. PT/ 12:30 p.m. ET

An audio webcast of the Company's presentation will be available by visiting the investor relations section of Endologix's website at www.endologix.com.  A replay of the presentation will be available for 30 days.

About Endologix, Inc.

Endologix, Inc. (the "Company") develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.

CONTACT: Endologix, Inc.
         John McDermott, CEO
         (949) 595-7200
         www.endologix.com
         
         INVESTOR CONTACTS:
         The Ruth Group
         Nick Laudico
         (646) 536-7030
         Zack Kubow
         (646) 536-7020